April 1, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has signed an agreement dated March 31, 2010 with JANSSEN PHARMACEUTICAL K.K. (Head Office: Tokyo, President: Toon Overstijns, hereinafter called “Janssen Pharma”) and Janssen Pharmaceutica N.V. (Head Office: Belgium, Managing Director: Tom Heyman) regarding co-marketing in Japan of galantamine (R113675), which is a drug for Alzheimer's Disease and chemically known as galantamine hydrobromide (hereinafter called “galantamine”).
Following the development of galantamine by Janssen Pharmaceutica, for the treatment of Alzheimer’s Disease in Japan, Janssen Pharma submitted an application for approval to the Ministry of Health, Labor and Welfare in February 2010.
Once approved, Takeda and Janssen Pharma will co-market galantamine under the same brand name... Takeda's Press Release - JANSSEN PHARMACEUTICAL K.K.'s Press Release [Japanese] -
